CIK 0001395937 · Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320162505
- Phone
- 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $113,716
- in 1 filing, $114K under 10b5-1 plans
Net −$113,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-08-18 | Podlesak Dennis Director | Sale 10b5-1 | −19,200 | $15.84 | $304K | 191,763 |
| 2025-08-18 | Podlesak Dennis Director | Option exercise · Stock Options (Right to buy) 10b5-1 | −19,200 | 0 | ||
| 2025-08-15 | Podlesak Dennis Director | Option exercise 10b5-1 | +19,200 | $7.20 | $138K | 210,963 |
| 2025-08-15 | Podlesak Dennis Director | Sale 10b5-1 | −19,200 | $15.54 | $298K | 191,763 |
| 2025-08-15 | Podlesak Dennis Director | Option exercise · Stock Options (Right to buy) 10b5-1 | −14,400 | 0 | ||
| 2025-08-15 | Podlesak Dennis Director | Option exercise · Stock Options (Right to buy) 10b5-1 | −4,800 | 0 | ||
| 2025-08-14 | Podlesak Dennis Director | Option exercise 10b5-1 | +19,200 | $7.20 | $138K | 210,963 |
| 2025-08-14 | Podlesak Dennis Director | Sale 10b5-1 | −19,200 | $14.19 | $273K | 191,763 |
| 2025-08-14 | Podlesak Dennis Director | Option exercise · Stock Options (Right to buy) 10b5-1 | −19,200 | 0 | ||
| 2025-07-31 | Goldan Keith A. Chief Financial Officer | Other acquisition | +1,226 | $8.43 | $10K | 93,676 |
| 2025-07-16 | Goldan Keith A. Chief Financial Officer | Sale | −1,296 | $9.29 | $12K | 92,450 |
| 2025-07-16 | Metzger Michael A Chief Executive Officer | Sale | −7,534 | $9.29 | $70K | 298,661 |
| 2025-05-19 | Goldan Keith A. Chief Financial Officer | Purchase | +3,000 | 93,746 | ||
| 2025-05-19 | Huber Martin H. Jr. Director | Purchase | +5,000 | $8.99 | $45K | 79,000 |
| 2025-05-19 | Katkin Keith Director | Purchase | +10,000 | $9.11 | $91K | 100,000 |
| 2025-05-16 | Botwood Nicholas A.J. Head of R&D, CMO | Purchase | +11,765 | $9.00 | $106K | 35,165 |
| 2025-03-14 | Metzger Michael A Chief Executive Officer | Option exercise | +6,074 | $7.20 | $44K | 306,195 |
| 2025-03-14 | Metzger Michael A Chief Executive Officer | Option exercise · Stock options (Right to buy) | +6,074 | 0 | ||
| 2025-03-04 | Metzger Michael A Chief Executive Officer | Option exercise 10b5-1 | +7,814 | $7.20 | $56K | 307,935 |
| 2025-03-04 | Metzger Michael A Chief Executive Officer | Sale 10b5-1 | −7,814 | $15.05 | $118K | 300,121 |
Page 3 of 15 · 290 trades